STC2 and cardiovascular disorder: On the other hand, stanniocalcin 2 (STC-2) has been depicted as an inhibitor of the proteolytic activity of PAPP-A, having been demonstrated multiple alterations of the PAPP-A/Stc-2 axis in a great variety of conditions, such as diabetes mellitus, cancer, and cardiovascular disorders [12].